- Main
Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma
- Hackett, Christopher S;
- Quigley, David A;
- Wong, Robyn A;
- Chen, Justin;
- Cheng, Christine;
- Song, Young K;
- Wei, Jun S;
- Pawlikowska, Ludmila;
- Bao, Yun;
- Goldenberg, David D;
- Nguyen, Kim;
- Gustafson, W Clay;
- Rallapalli, Sundari K;
- Cho, Yoon-Jae;
- Cook, James M;
- Kozlov, Serguei;
- Mao, Jian-Hua;
- Van Dyke, Terry;
- Kwok, Pui-Yan;
- Khan, Javed;
- Balmain, Allan;
- Fan, QiWen;
- Weiss, William A
- et al.
Published Web Location
https://doi.org/10.1016/j.celrep.2014.09.046Abstract
The development of targeted therapeutics for neuroblastoma, the third most common tumor in children, has been limited by a poor understanding of growth signaling mechanisms unique to the peripheral nerve precursors from which tumors arise. In this study, we combined genetics with gene-expression analysis in the peripheral sympathetic nervous system to implicate arginase 1 and GABA signaling in tumor formation in vivo. In human neuroblastoma cells, either blockade of ARG1 or benzodiazepine-mediated activation of GABA-A receptors induced apoptosis and inhibited mitogenic signaling through AKT and MAPK. These results suggest that ARG1 and GABA influence both neural development and neuroblastoma and that benzodiazepines in clinical use may have potential applications for neuroblastoma therapy.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-